Recorna Bio is focused on pioneering RNA editing therapies aimed at treating various diseases. Their innovative approach leverages RNA editing technology, which allows for precise modifications to RNA molecules. This technology has the potential to correct genetic mutations at the RNA level, offering a novel strategy for addressing genetic disorders and other diseases that are currently difficult to treat. The recognition of their project in the China Innovation and Entrepreneurship Competition highlights the promise and potential impact of their work in the field of biotechnology.

In addition to their technological advancements, Recorna Bio has successfully completed an angel funding round, securing millions of USD to support their research and development efforts. The company has established its headquarters at the BeiGene Bioisland Innovation Center, positioning itself within a vibrant ecosystem of biotech innovation. This strategic location not only facilitates collaboration with other biotech firms but also enhances their visibility and access to resources necessary for advancing their RNA editing therapies.

China

Recorna Bio is a researcher and developer of RNA-edited drugs, focusing on drug discovery and development by targeting RNA editing cutting-edge technology. The company has completed millions of USD in Angel round funding and collaborates with other RNA companies to discover novel therapies for lung disease.

Recorna Bio

Company Details